ReviewDrug safety1994
Clinical trials and transethnic pharmacology.
Review in Drug safety, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.British journal of clinical pharmacology · 2000Trial
- Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.Clinical pharmacokinetics · 2006Review
- Mechanisms of clinically relevant drug interactions associated with tacrolimus.Clinical pharmacokinetics · 2002Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is generally agreed that the advance of a global economy must be accompanied by global drug development. Thus, more intense effort, time and expense must be given to the study of overall global population, which will ultimately be exposed to the drug in development. Race and ethnicity of the ultimate drug consumer must be evaluated, and not only in broad terms. Ethnic and racial representations must be considered in clinical trials. The differences in response to drug action in various ethnic and racial groups must be evaluated to provide information for the physician in practice, who is faced with an increasingly nonhomogeneous population, and who must prescribe medications for those patients. The practising physician urgently requires international, crosscultural collaborative studies, using standardised methods applicable to different cultural settings.
Indexed as
Identifiers
7873093What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.